Vaxart, Inc. (VXRT)
USD 0.29
(-12.84%)
USD 0.29
(-12.84%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -74.72 Million USD | 18.14% |
| 2022 | -103.11 Million USD | -56.19% |
| 2021 | -66.45 Million USD | -118.42% |
| 2020 | -28.26 Million USD | -296.54% |
| 2019 | -12.17 Million USD | 56.94% |
| 2018 | -12.01 Million USD | -89.31% |
| 2017 | -8.73 Million USD | 67.77% |
| 2016 | -27.2 Million USD | -9.27% |
| 2015 | -25 Million USD | -264.71% |
| 2014 | -18.1 Million USD | 9.33% |
| 2013 | -8.9 Million USD | 71.26% |
| 2012 | -16.6 Million USD | -179.71% |
| 2011 | -7.51 Million USD | -1476.18% |
| 2010 | -301 Thousand USD | 96.54% |
| 2009 | -17.15 Million USD | 13.68% |
| 2008 | -21.27 Million USD | 57.64% |
| 2007 | -33.6 Million USD | 22.42% |
| 2006 | -53.71 Million USD | 33.98% |
| 2005 | -107.27 Million USD | -168.0% |
| 2004 | -33.86 Million USD | -193.78% |
| 2003 | 19.71 Million USD | -6.59% |
| 2002 | 25.86 Million USD | 63.38% |
| 2001 | 126.5 Million USD | 154.77% |
| 2000 | 13.41 Million USD | -33.72% |
| 1999 | 15.9 Million USD | -43.15% |
| 1998 | 10.1 Million USD | 155.67% |
| 1997 | 4.2 Million USD | -46.99% |
| 1996 | 19.1 Million USD | 654.55% |
| 1995 | -2.6 Million USD | -115.14% |
| 1994 | 21.8 Million USD | 89.57% |
| 1993 | 11.5 Million USD | 130.0% |
| 1992 | 5 Million USD | 19.05% |
| 1991 | 4.5 Million USD | -2.17% |
| 1990 | 4.6 Million USD | 58.62% |
| 1989 | 2.9 Million USD | 38.1% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -22.97 Million USD | -44.73% |
| 2024 Q2 | -15.15 Million USD | 35.86% |
| 2023 Q3 | -15.08 Million USD | 25.21% |
| 2023 Q1 | -22.86 Million USD | -31.15% |
| 2023 Q2 | -20.17 Million USD | 11.77% |
| 2023 Q4 | -15.7 Million USD | -4.05% |
| 2023 FY | - USD | 18.14% |
| 2022 Q1 | -23.61 Million USD | -45.74% |
| 2022 Q4 | -17.43 Million USD | 36.37% |
| 2022 Q3 | -27.4 Million USD | 1.66% |
| 2022 Q2 | -27.86 Million USD | -18.04% |
| 2022 FY | - USD | -56.19% |
| 2021 Q1 | -14.5 Million USD | -16.13% |
| 2021 Q2 | -14.75 Million USD | -1.74% |
| 2021 FY | - USD | -118.42% |
| 2021 Q4 | -16.2 Million USD | 0.02% |
| 2021 Q3 | -16.2 Million USD | -9.79% |
| 2020 Q1 | -9000.00 USD | -110.23% |
| 2020 Q2 | -7.85 Million USD | -87133.33% |
| 2020 Q4 | -12.49 Million USD | -58.45% |
| 2020 Q3 | -7.88 Million USD | -0.41% |
| 2020 FY | - USD | -296.54% |
| 2019 Q1 | 657 Thousand USD | 121.17% |
| 2019 Q2 | -3.96 Million USD | -703.65% |
| 2019 Q3 | -3.89 Million USD | 1.69% |
| 2019 Q4 | 88 Thousand USD | 102.26% |
| 2019 FY | - USD | 56.94% |
| 2018 Q4 | -3.1 Million USD | 35.64% |
| 2018 FY | - USD | -89.31% |
| 2018 Q1 | -3.39 Million USD | -17.21% |
| 2018 Q2 | -5.21 Million USD | -53.37% |
| 2018 Q3 | -4.82 Million USD | 7.52% |
| 2017 FY | - USD | 67.77% |
| 2017 Q3 | -4.9 Million USD | 10.91% |
| 2017 Q4 | -2.9 Million USD | 40.82% |
| 2017 Q2 | -5.5 Million USD | -52.78% |
| 2017 Q1 | -3.6 Million USD | 57.14% |
| 2016 FY | - USD | -9.27% |
| 2016 Q4 | -8.4 Million USD | 13.4% |
| 2016 Q3 | -9.7 Million USD | -44.78% |
| 2016 Q2 | -6.7 Million USD | -21.82% |
| 2016 Q1 | -5.5 Million USD | 17.91% |
| 2015 FY | - USD | -264.71% |
| 2015 Q4 | -6.7 Million USD | -26.42% |
| 2015 Q1 | -5.6 Million USD | -247.37% |
| 2015 Q2 | 15.2 Million USD | 371.43% |
| 2015 Q3 | -5.3 Million USD | -134.87% |
| 2014 Q3 | -9.2 Million USD | -16.46% |
| 2014 Q1 | 4.4 Million USD | 2100.0% |
| 2014 Q4 | 3.8 Million USD | 141.3% |
| 2014 FY | - USD | 9.33% |
| 2014 Q2 | -7.9 Million USD | -279.55% |
| 2013 Q2 | -9.69 Million USD | -1137.22% |
| 2013 FY | - USD | 71.26% |
| 2013 Q4 | 200 Thousand USD | 106.67% |
| 2013 Q3 | -3 Million USD | 69.07% |
| 2013 Q1 | 935 Thousand USD | 108.35% |
| 2012 FY | - USD | -179.71% |
| 2012 Q2 | -2.85 Million USD | -31.16% |
| 2012 Q3 | -4.11 Million USD | -44.02% |
| 2012 Q1 | -2.17 Million USD | -17.02% |
| 2012 Q4 | -11.2 Million USD | -172.16% |
| 2011 Q4 | -1.86 Million USD | 62.0% |
| 2011 Q1 | 1.89 Million USD | 130.43% |
| 2011 Q2 | -4.68 Million USD | -346.45% |
| 2011 Q3 | -4.9 Million USD | -4.7% |
| 2011 FY | - USD | -1476.18% |
| 2010 Q3 | 3.43 Million USD | 199.62% |
| 2010 FY | - USD | 96.54% |
| 2010 Q4 | -6.24 Million USD | -281.79% |
| 2010 Q2 | -3.44 Million USD | -164.95% |
| 2010 Q1 | 5.3 Million USD | 187.28% |
| 2009 FY | - USD | 13.68% |
| 2009 Q1 | -6.7 Million USD | -4.83% |
| 2009 Q4 | 1.84 Million USD | 127.05% |
| 2009 Q2 | -5.71 Million USD | 14.77% |
| 2009 Q3 | -6.82 Million USD | -19.46% |
| 2008 Q4 | -6.39 Million USD | -9.18% |
| 2008 Q3 | -5.85 Million USD | 26.26% |
| 2008 Q2 | -7.94 Million USD | 4.53% |
| 2008 Q1 | -8.32 Million USD | 16.37% |
| 2008 FY | - USD | 57.64% |
| 2007 Q3 | -11.32 Million USD | -2.32% |
| 2007 Q4 | -9.95 Million USD | 12.14% |
| 2007 Q1 | -8.97 Million USD | -15.4% |
| 2007 Q2 | -11.06 Million USD | -23.39% |
| 2007 FY | - USD | 22.42% |
| 2006 Q4 | -7.77 Million USD | 12.45% |
| 2006 FY | - USD | 33.98% |
| 2006 Q3 | -8.87 Million USD | 26.68% |
| 2006 Q2 | -12.1 Million USD | 10.05% |
| 2006 Q1 | -13.46 Million USD | 43.26% |
| 2005 Q2 | -23.17 Million USD | -27.22% |
| 2005 FY | - USD | -168.0% |
| 2005 Q1 | -18.21 Million USD | -187.07% |
| 2005 Q4 | -23.72 Million USD | -31.35% |
| 2005 Q3 | -18.06 Million USD | 22.08% |
| 2004 Q4 | 20.92 Million USD | 3447.84% |
| 2004 Q3 | -625 Thousand USD | -108.43% |
| 2004 Q1 | 992 Thousand USD | -96.35% |
| 2004 Q2 | 7.41 Million USD | 647.08% |
| 2004 FY | - USD | -193.78% |
| 2003 FY | - USD | -6.59% |
| 2003 Q4 | 10.52 Million USD | 257.23% |
| 2003 Q3 | 7.62 Million USD | 579.76% |
| 2003 Q2 | -1.57 Million USD | -150.57% |
| 2003 Q1 | 519 Thousand USD | -89.11% |
| 2002 Q4 | 15.92 Million USD | 707.09% |
| 2002 Q1 | 4.26 Million USD | -48.49% |
| 2002 Q2 | 3.45 Million USD | -14.45% |
| 2002 Q3 | 1.01 Million USD | -2.03% |
| 2002 FY | - USD | 63.38% |
| 2001 FY | - USD | 154.77% |
| 2001 Q4 | 8.03 Million USD | 45.52% |
| 2001 Q3 | 109.88 Million USD | 22.79% |
| 2001 Q2 | 4.62 Million USD | 16.41% |
| 2001 Q1 | 3.94 Million USD | 156.2% |
| 2000 Q4 | -464 Thousand USD | -109.82% |
| 2000 FY | - USD | -33.72% |
| 2000 Q1 | 4.05 Million USD | -17.0% |
| 2000 Q2 | 4.46 Million USD | 12.05% |
| 2000 Q3 | -369 Thousand USD | -175.47% |
| 1999 FY | - USD | -43.15% |
| 1999 Q4 | 4.8 Million USD | 500.0% |
| 1999 Q3 | 2.7 Million USD | -84.9% |
| 1999 Q1 | 3.12 Million USD | -82.84% |
| 1999 Q2 | 5.29 Million USD | 69.64% |
| 1998 FY | - USD | 155.67% |
| 1998 Q1 | 600 Thousand USD | 117.95% |
| 1998 Q2 | 3.1 Million USD | 314.29% |
| 1998 Q4 | 3.4 Million USD | 468.75% |
| 1998 Q3 | 3.2 Million USD | 10.34% |
| 1997 Q1 | 5 Million USD | -31.43% |
| 1997 Q3 | -2.4 Million USD | -42.11% |
| 1997 Q4 | -3.9 Million USD | -218.18% |
| 1997 FY | - USD | -46.99% |
| 1997 Q2 | 5.7 Million USD | 18.75% |
| 1996 FY | - USD | 654.55% |
| 1996 Q2 | 4.2 Million USD | -2.63% |
| 1996 Q3 | 3.9 Million USD | -2.7% |
| 1996 Q4 | 6.7 Million USD | 94.44% |
| 1996 Q1 | 4.1 Million USD | 116.38% |
| 1995 Q3 | 7.4 Million USD | 5.71% |
| 1995 Q4 | -23.2 Million USD | -413.51% |
| 1995 Q1 | 6.3 Million USD | 1.61% |
| 1995 Q2 | 7 Million USD | 11.11% |
| 1995 FY | - USD | -115.14% |
| 1994 Q2 | 5.5 Million USD | 22.22% |
| 1994 FY | - USD | 89.57% |
| 1994 Q4 | 6.2 Million USD | 10.71% |
| 1994 Q1 | 4.5 Million USD | 18.42% |
| 1994 Q3 | 5.6 Million USD | 1.82% |
| 1993 Q3 | 2.4 Million USD | -25.0% |
| 1993 Q4 | 3.8 Million USD | 58.33% |
| 1993 Q1 | 2 Million USD | 5.26% |
| 1993 Q2 | 3.2 Million USD | 60.0% |
| 1993 FY | - USD | 130.0% |
| 1992 Q1 | 1.1 Million USD | -8.33% |
| 1992 Q4 | 1.9 Million USD | 311.11% |
| 1992 FY | - USD | 19.05% |
| 1992 Q2 | 1.9 Million USD | 72.73% |
| 1992 Q3 | -100 Thousand USD | -147.37% |
| 1991 Q4 | 1.2 Million USD | 33.33% |
| 1991 FY | - USD | 5.0% |
| 1991 Q1 | 1.1 Million USD | -9.09% |
| 1991 Q2 | 1.1 Million USD | 0.0% |
| 1991 Q3 | 1 Million USD | -10.0% |
| 1990 FY | - USD | 90.48% |
| 1990 Q4 | 1.2 Million USD | 22.22% |
| 1990 Q3 | 1.1 Million USD | -18.18% |
| 1990 Q2 | 1.2 Million USD | 37.5% |
| 1990 Q1 | 1 Million USD | 14.29% |
| 1989 Q4 | 1 Million USD | -12.5% |
| 1989 FY | - USD | -19.23% |
| 1989 Q1 | 13.6 Million USD | 139.31% |
| 1989 Q3 | 900 Thousand USD | 14.29% |
| 1989 Q2 | 900 Thousand USD | -94.85% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbCellera Biologics Inc. | -192.15 Million USD | 61.114% |
| Alkermes plc | 495.04 Million USD | 115.094% |
| Agenus Inc. | -145.92 Million USD | 48.793% |
| Aptorum Group Limited | -9.59 Million USD | -678.446% |
| Ardelyx, Inc. | -55.35 Million USD | -34.991% |
| Dyadic International, Inc. | -8.22 Million USD | -807.963% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -25578.007% |
| Lantern Pharma Inc. | -15.78 Million USD | -373.329% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | -275.259% |
| Novavax, Inc. | -487.39 Million USD | 84.669% |
| Janux Therapeutics, Inc. | -71.02 Million USD | -5.208% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 4.803% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | -315.741% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | -649.629% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | -30.234% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 80.334% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -209.901% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 14225.331% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 52.465% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 0.123% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -270.668% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | -214.822% |
| Clearside Biomedical, Inc. | -23.05 Million USD | -224.065% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 38.803% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 71.065% |
| AlloVir, Inc. | -190.14 Million USD | 60.702% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 57.464% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -155.393% |
| Bicycle Therapeutics plc | -183.4 Million USD | 59.257% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 54.829% |
| ChromaDex Corporation | -3.89 Million USD | -1818.927% |
| Chimerix, Inc. | -92.97 Million USD | 19.63% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -68.156% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 33.6% |
| CRISPR Therapeutics AG | -202.7 Million USD | 63.136% |
| Precision BioSciences, Inc. | -32.04 Million USD | -133.203% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 56.614% |
| Fortress Biotech, Inc. | -133.64 Million USD | 44.088% |
| Fortress Biotech, Inc. | -133.64 Million USD | 44.088% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 3.388% |
| ImmuCell Corporation | -2.5 Million USD | -2884.054% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 42.706% |
| Immix Biopharma, Inc. | -16.13 Million USD | -363.093% |
| Incyte Corporation | 919.42 Million USD | 108.127% |
| Innoviva, Inc. | 248.96 Million USD | 130.014% |
| IO Biotech, Inc. | -91.22 Million USD | 18.092% |
| Jaguar Health, Inc. | -33.13 Million USD | -125.538% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 50.897% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 173.454% |
| ContextLogic Inc. | -324 Million USD | 76.937% |
| MiMedx Group, Inc. | 40.51 Million USD | 284.424% |
| MEI Pharma, Inc. | 26.38 Million USD | 383.256% |
| NextCure, Inc. | -59.03 Million USD | -26.565% |
| Onconetix, Inc. | -36.7 Million USD | -103.568% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 3443.311% |
| Opthea Limited | -200.01 Million USD | 62.642% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -2615.64% |
| Vaxcyte, Inc. | -464.88 Million USD | 83.927% |
| PDS Biotechnology Corporation | -40.08 Million USD | -86.412% |
| Precigen, Inc. | -89.22 Million USD | 16.254% |
| Pharming Group N.V. | 9.87 Million USD | 856.535% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 53.019% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | -228.28% |
| PureTech Health plc | -11.62 Million USD | -542.668% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | -340.039% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 67.998% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -209.901% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 14.531% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | -157.995% |
| Acelyrin, Inc. | -381.52 Million USD | 80.415% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -579827.341% |
| Summit Therapeutics Inc. | 1 Million USD | 7564.835% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | -123.815% |
| Senti Biosciences, Inc. | -61.33 Million USD | -21.826% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 33.464% |
| Elevation Oncology, Inc. | -41.46 Million USD | -80.199% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | -141.791% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | -1121.654% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -23178.193% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | -130.25% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | -789.983% |
| Wave Life Sciences Ltd. | -58.79 Million USD | -27.102% |
| Seer, Inc. | -97.88 Million USD | 23.662% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | -20.139% |
| Aadi Bioscience, Inc. | -65.36 Million USD | -14.317% |
| ESSA Pharma Inc. | -26.45 Million USD | -182.45% |
| GlycoMimetics, Inc. | -39.12 Million USD | -91.0% |
| GT Biopharma, Inc. | 5.97 Million USD | 1349.757% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 63.848% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | -987.988% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 186.075% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -31.661% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | -45.889% |
| Alzamend Neuro, Inc. | -9.88 Million USD | -655.777% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 86.161% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -985.459% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | -59.453% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 68.421% |
| Aptose Biosciences Inc. | -52.26 Million USD | -42.961% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 30.647% |
| Soligenix, Inc. | -7.85 Million USD | -851.54% |
| Century Therapeutics, Inc. | -121.2 Million USD | 38.351% |
| Kura Oncology, Inc. | -164.95 Million USD | 54.701% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 6.711% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | -640.859% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -7702.021% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | -1634.115% |
| Autolus Therapeutics plc | -156.77 Million USD | 52.336% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 11.734% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | -8.293% |
| Eterna Therapeutics Inc. | -19.93 Million USD | -274.852% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 60.521% |
| GRI Bio, Inc. | -10.89 Million USD | -585.658% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -1554.732% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 39.005% |
| IGM Biosciences, Inc. | -253.35 Million USD | 70.507% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 28.007% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -95.953% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -387.401% |
| Entero Therapeutics, Inc. | -15.74 Million USD | -374.635% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | -31.45% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 30.233% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 71.908% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 61.471% |
| Verastem, Inc. | -83.16 Million USD | 10.152% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -47.756% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 52.775% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 34.505% |
| Histogen Inc. | -10.5 Million USD | -611.444% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | -423.281% |
| Surrozen, Inc. | -41.13 Million USD | -81.671% |
| Organovo Holdings, Inc. | -14.8 Million USD | -404.681% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 2330096.882% |
| Ovid Therapeutics Inc. | -58.71 Million USD | -27.268% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -45.676% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | -246.92% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | -796.174% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 55.004% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | -51.696% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | -209.207% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | -396.332% |
| Apollomics, Inc. | -171.74 Million USD | 56.492% |
| Amarin Corporation plc | -50.9 Million USD | -46.799% |
| Mesoblast Limited | -61.33 Million USD | -21.836% |
| Turnstone Biologics Corp. | -56.23 Million USD | -32.879% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 47.819% |
| Synaptogenix, Inc. | -8.3 Million USD | -799.464% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | -387.144% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | -18.52% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -1459.502% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 17516.365% |
| Exelixis, Inc. | 196.6 Million USD | 138.007% |
| Better Therapeutics, Inc. | -38.26 Million USD | -95.293% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 47.158% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 84.911% |
| NLS Pharmaceutics AG | -11.79 Million USD | -533.479% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 30325.794% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -153.247% |
| Gritstone bio, Inc. | -126.86 Million USD | 41.099% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -14.985% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -1768.1% |
| Avid Bioservices, Inc. | -11.48 Million USD | -550.841% |
| Insmed Incorporated | -654.73 Million USD | 88.587% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -3221.437% |
| MediWound Ltd. | -4.89 Million USD | -1427.141% |
| OmniAb, Inc. | -49.73 Million USD | -50.254% |
| Alector, Inc. | -142.89 Million USD | 47.707% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 12.537% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -43.29% |
| Zai Lab Limited | -366.57 Million USD | 79.616% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 74.29% |
| Aura Biosciences, Inc. | -83.69 Million USD | 10.721% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 66.826% |
| Immunic, Inc. | -99.11 Million USD | 24.608% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 43.25% |
| Veracyte, Inc. | -49.4 Million USD | -51.234% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | -957.81% |
| FibroGen, Inc. | -261.4 Million USD | 71.415% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -570.703% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -967.269% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | -299.228% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 105.155% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | -193.93% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 287.323% |
| TG Therapeutics, Inc. | 26.1 Million USD | 386.295% |
| Galecto, Inc. | -37.51 Million USD | -99.16% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -95.278% |
| Fortrea Holdings Inc. | 167.3 Million USD | 144.664% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 44.353% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | -163.936% |
| XBiotech Inc. | -35.76 Million USD | -108.922% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -14.985% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | -14.518% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 28.464% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -191.068% |
| Theravance Biopharma, Inc. | -40.86 Million USD | -82.844% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 85.532% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | -33.384% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -133212.519% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 35.769% |
| Gain Therapeutics, Inc. | -22.16 Million USD | -237.052% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 68.212% |
| NexImmune, Inc. | -28.16 Million USD | -165.281% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | -1252.318% |
| Marker Therapeutics, Inc. | -11.79 Million USD | -533.661% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 101.605% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | -194.278% |
| Scopus BioPharma Inc. | -11.71 Million USD | -537.941% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 40.623% |
| Ainos, Inc. | -8.77 Million USD | -751.729% |
| Pluri Inc. | -20.22 Million USD | -269.459% |
| Prothena Corporation plc | -190.1 Million USD | 60.694% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 41.713% |
| Celularity Inc. | -183.94 Million USD | 59.378% |
| Rallybio Corporation | -72.37 Million USD | -3.247% |
| Cue Biopharma, Inc. | -46.05 Million USD | -62.258% |
| MeiraGTx Holdings plc | -57.05 Million USD | -30.973% |
| Omeros Corporation | -163.61 Million USD | 54.329% |
| Humacyte, Inc. | -96.45 Million USD | 22.533% |
| Immunocore Holdings plc | -59.64 Million USD | -25.271% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | -285.727% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | -206.682% |
| Blueprint Medicines Corporation | -474.61 Million USD | 84.256% |
| CalciMedica, Inc. | -34.18 Million USD | -118.559% |
| Cabaletta Bio, Inc. | -73.23 Million USD | -2.033% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 40.458% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 55.641% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 70.394% |
| Pulmatrix, Inc. | -12.64 Million USD | -490.882% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | -126.667% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 15.536% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 85.242% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 26.174% |
| Cytokinetics, Incorporated | -456.68 Million USD | 83.638% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -123.903% |
| Nutriband Inc. | -5.12 Million USD | -1358.927% |
| Protara Therapeutics, Inc. | -43.27 Million USD | -72.682% |
| Vor Biopharma Inc. | -114.37 Million USD | 34.666% |
| Roivant Sciences Ltd. | -996.51 Million USD | 92.502% |
| Evogene Ltd. | -23.2 Million USD | -222.026% |
| ProKidney Corp. | -147.66 Million USD | 49.398% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -15.787% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -48691.047% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 86.786% |
| CorMedix Inc. | -48.88 Million USD | -52.848% |
| BioLineRx Ltd. | -57.06 Million USD | -30.953% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 33.139% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -36891.584% |
| Atai Life Sciences N.V. | -36.31 Million USD | -105.786% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 6.029% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 8.104% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 72.878% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -143.081% |
| MediciNova, Inc. | -9.87 Million USD | -656.308% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 40.668% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -4783.215% |
| GeoVax Labs, Inc. | -26.66 Million USD | -180.189% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 66.788% |
| Biomea Fusion, Inc. | -124.62 Million USD | 40.039% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 77.38% |
| Mereo BioPharma Group plc | -26.05 Million USD | -186.778% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 60.742% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 67.504% |
| Absci Corporation | -95.45 Million USD | 21.721% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -148.869% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 30.242% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 67.995% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | -226.944% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 64.047% |
| Allakos Inc. | -189.91 Million USD | 60.655% |
| Imunon, Inc. | -19.87 Million USD | -275.903% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 31.126% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 168.981% |
| BioAtla, Inc. | -122.24 Million USD | 38.872% |
| NLS Pharmaceutics AG | -11.79 Million USD | -533.479% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -374.101% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 75.117% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | -80.286% |
| XOMA Corporation | -39.36 Million USD | -89.835% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 24.715% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 36.487% |
| aTyr Pharma, Inc. | -52.17 Million USD | -43.208% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 10.848% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 49.726% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 68.144% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | -447.301% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | -829.125% |
| Akari Therapeutics, Plc | -16.8 Million USD | -344.727% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 39697.575% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 116.534% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -1069.626% |
| UroGen Pharma Ltd. | -63.83 Million USD | -17.064% |
| Sutro Biopharma, Inc. | -67.91 Million USD | -10.024% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -928.816% |
| Orgenesis Inc. | -60.71 Million USD | -23.066% |
| Entera Bio Ltd. | -8.8 Million USD | -748.739% |
| GH Research PLC | -41.15 Million USD | -81.574% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | -192.813% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 9.133% |
| Xencor, Inc. | -125.87 Million USD | 40.637% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -5138.04% |
| Replimune Group, Inc. | -230.19 Million USD | 67.54% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | -270.694% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | -582.901% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -1069.626% |
| Portage Biotech Inc. | -18.19 Million USD | -310.588% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -4783.215% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 28.552% |
| OncoCyte Corporation | -23.12 Million USD | -223.154% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -561.244% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -552.213% |
| Purple Biotech Ltd. | -22.22 Million USD | -236.211% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | -1065.725% |
| scPharmaceuticals Inc. | -46.06 Million USD | -62.226% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | -319.564% |
| HilleVax, Inc. | -132.46 Million USD | 43.591% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | -602.746% |
| Tharimmune, Inc. | -9.3 Million USD | -703.25% |
| Genprex, Inc. | -31.06 Million USD | -140.572% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 60.153% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | -138.32% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -9680.497% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 49616.911% |
| OKYO Pharma Limited | -15.74 Thousand USD | -474456.185% |
| Savara Inc. | -59.13 Million USD | -26.364% |
| Curis, Inc. | -45.13 Million USD | -65.54% |
| Daré Bioscience, Inc. | -30.7 Million USD | -143.385% |
| Carmell Therapeutics Corporation | -15.19 Million USD | -391.885% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | -942.889% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | -179.505% |
| BeiGene, Ltd. | -1.12 Billion USD | 93.356% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -358.39% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 82.646% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 17.287% |
| Erasca, Inc. | -121.31 Million USD | 38.403% |
| bluebird bio, Inc. | -167.16 Million USD | 55.299% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -1560.97% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 124.082% |
| DBV Technologies S.A. | -85.98 Million USD | 13.095% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -1560.97% |
| Moderna, Inc. | -3.28 Billion USD | 97.724% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -75.369% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | -1222.999% |
| Molecular Templates, Inc. | 1.43 Million USD | 5325.385% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | -24.846% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 77.096% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 45.493% |
| Spruce Biosciences, Inc. | -47.36 Million USD | -57.757% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 46.256% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 63.702% |
| MacroGenics, Inc. | 2.01 Million USD | 3804.66% |
| RenovoRx, Inc. | -11.39 Million USD | -556.04% |
| Adicet Bio, Inc. | -136.53 Million USD | 45.272% |
| Prime Medicine, Inc. | -193.75 Million USD | 61.435% |
| Aditxt, Inc. | -25.45 Million USD | -193.515% |
| Adagene Inc. | -14.95 Million USD | -399.793% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -922.189% |
| Quantum-Si incorporated | -91.8 Million USD | 18.606% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 110.489% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 159.091% |
| SciSparc Ltd. | -5.28 Million USD | -1314.672% |
| Vericel Corporation | 2.86 Million USD | 2709.043% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -78383.951% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | -244.482% |
| Generation Bio Co. | -133.3 Million USD | 43.944% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 10.005% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 13.136% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 67.145% |
| Invivyd, Inc. | -196.61 Million USD | 61.995% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 80.029% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | -705.656% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 375.182% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -626.524% |
| 2seventy bio, Inc. | -206.41 Million USD | 63.8% |
| ADMA Biologics, Inc. | 5.12 Million USD | 1559.434% |
| Clene Inc. | -43.24 Million USD | -72.806% |
| Capricor Therapeutics, Inc. | -23 Million USD | -224.756% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | -54.141% |
| GeoVax Labs, Inc. | -26.66 Million USD | -180.189% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 75.056% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | -103.442% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 416.986% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 1621.774% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -130.044% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 52.828% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 89.08% |
| Evaxion Biotech A/S | -21.4 Million USD | -249.124% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | -12.509% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 65.671% |
| Trevena, Inc. | -35.28 Million USD | -111.752% |
| Surrozen, Inc. | -41.13 Million USD | -81.671% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 6.117% |
| Cingulate Inc. | -22.95 Million USD | -225.562% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | -901.515% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -100.421% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | -808.335% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 26.933% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | -10.167% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | -28.012% |
| Clearmind Medicine Inc. | -8.71 Million USD | -757.834% |
| Kronos Bio, Inc. | -121.83 Million USD | 38.666% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | -0.512% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -2960.644% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 25.89% |
| Statera Biopharma, Inc. | 38.93 Million USD | 291.918% |
| ImmunityBio, Inc. | -436.18 Million USD | 82.869% |
| Korro Bio, Inc. | -80.9 Million USD | 7.64% |
| Kineta, Inc. | -15.71 Million USD | -375.519% |
| BioVie Inc. | -31.95 Million USD | -133.873% |
| Codexis, Inc. | -49.28 Million USD | -51.62% |
| Celularity Inc. | -183.94 Million USD | 59.378% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 66.267% |
| Celcuity Inc. | -58.3 Million USD | -28.148% |
| Virax Biolabs Group Limited | -6.6 Million USD | -1030.6% |
| Cibus, Inc. | -314.58 Million USD | 76.247% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -121.513% |
| IN8bio, Inc. | -28.5 Million USD | -162.149% |
| Kodiak Sciences Inc. | -259.02 Million USD | 71.152% |
| Annexon, Inc. | -141.57 Million USD | 47.22% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 33.638% |
| Assembly Biosciences, Inc. | -64.19 Million USD | -16.398% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | -167.297% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 67.513% |
| Eyenovia, Inc. | -24.1 Million USD | -209.976% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 266.852% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -22962.654% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | -1.245% |
| Arcellx, Inc. | -64.14 Million USD | -16.491% |
| Cardiff Oncology, Inc. | -45.01 Million USD | -65.999% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 39.484% |
| Regulus Therapeutics Inc. | -30.88 Million USD | -141.963% |
| Moolec Science SA | -52.07 Million USD | -43.49% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | -44.795% |
| Geron Corporation | -174.78 Million USD | 57.248% |
| LAVA Therapeutics N.V. | -40.41 Million USD | -84.88% |
| Royalty Pharma plc | 1.88 Billion USD | 103.959% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 37.519% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -701.383% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | -260.271% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 55.008% |
| Humacyte, Inc. | -96.45 Million USD | 22.533% |
| Structure Therapeutics Inc. | -102.45 Million USD | 27.07% |
| 89bio, Inc. | -134.46 Million USD | 44.429% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 5.264% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 1944.102% |
| Genelux Corporation | -24.16 Million USD | -209.22% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | -121.074% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 54.288% |
| Notable Labs, Ltd. | -14.4 Million USD | -418.91% |
| Liquidia Corporation | -70.05 Million USD | -6.669% |
| Mustang Bio, Inc. | -48.06 Million USD | -55.469% |
| Immunovant, Inc. | -269.97 Million USD | 72.323% |
| Quantum-Si incorporated | -91.8 Million USD | 18.606% |
| Arbutus Biopharma Corporation | -70.98 Million USD | -5.264% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | -287.005% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 26.751% |
| Acasti Pharma Inc. | -11.3 Million USD | -561.207% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | -235.785% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -387.401% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 64.504% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | -1649.813% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -370.548% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | -159.671% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | -101.79% |
| PepGen Inc. | -83.58 Million USD | 10.599% |
| Moleculin Biotech, Inc. | -29.5 Million USD | -153.264% |
| United Therapeutics Corporation | 1.38 Billion USD | 105.388% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -226.344% |
| Solid Biosciences Inc. | -93.43 Million USD | 20.026% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | -1465.95% |
| Immuneering Corporation | -58.06 Million USD | -28.698% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 2330096.882% |
| Silo Pharma, Inc. | -3.62 Million USD | -1960.634% |
| Belite Bio, Inc | -31.52 Million USD | -136.998% |
| XOMA Corporation | -39.36 Million USD | -89.835% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | -10.788% |
| Bionomics Limited | -9.83 Million USD | -659.612% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 11.028% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -115.925% |
| uniQure N.V. | -253.1 Million USD | 70.477% |
| Cassava Sciences, Inc. | -95.68 Million USD | 21.909% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -922.189% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 42.301% |
| Forte Biosciences, Inc. | -32.47 Million USD | -130.08% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | -828.181% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | -164.797% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -22962.654% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -570.703% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | -369.926% |
| Altimmune, Inc. | -87.93 Million USD | 15.025% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 18.849% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -115.925% |
| Compugen Ltd. | -12.51 Million USD | -497.02% |
| Peak Bio, Inc. | -1356.23 USD | -5509511.202% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | -53.757% |
| Benitec Biopharma Inc. | -22.49 Million USD | -232.25% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 69.161% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | -161.791% |
| Zura Bio Limited | -60.56 Million USD | -23.381% |
| PolyPid Ltd. | -20.26 Million USD | -268.766% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | -378.595% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | -161.791% |
| Instil Bio, Inc. | -146.12 Million USD | 48.863% |
| argenx SE | -216.02 Million USD | 65.41% |
| Immunome, Inc. | -28.27 Million USD | -164.31% |
| Compass Therapeutics, Inc. | -48.47 Million USD | -54.154% |
| Verona Pharma plc | -52.46 Million USD | -42.417% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 21.155% |
| Shattuck Labs, Inc. | -87.61 Million USD | 14.714% |
| CervoMed Inc. | -2.17 Million USD | -3340.485% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 38.874% |
| Plus Therapeutics, Inc. | -12.69 Million USD | -488.695% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -55.111% |
| Moolec Science SA | -52.07 Million USD | -43.49% |
| Enveric Biosciences, Inc. | -17.13 Million USD | -335.957% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 42.693% |
| AnaptysBio, Inc. | -143.16 Million USD | 47.806% |
| Design Therapeutics, Inc. | -66.32 Million USD | -12.662% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 7.735% |
| NeurAxis, Inc. | -6.66 Million USD | -1021.21% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | -97.942% |
| Lumos Pharma, Inc. | -36.57 Million USD | -104.329% |
| Achilles Therapeutics plc | -70.44 Million USD | -6.077% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 21.155% |
| 180 Life Sciences Corp. | -22.13 Million USD | -237.593% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 1381.864% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -2960.644% |
| Nutriband Inc. | -5.12 Million USD | -1358.927% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 31.914% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | -34.801% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | -47.82% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | -14.471% |
| MoonLake Immunotherapeutics | -54.1 Million USD | -38.095% |
| Palisade Bio, Inc. | -12.28 Million USD | -508.444% |
| Tourmaline Bio, Inc. | -45.37 Million USD | -64.675% |
| Beam Therapeutics Inc. | -156.47 Million USD | 52.245% |
| Neurogene Inc. | -52.28 Million USD | -42.912% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 45.254% |
| AEON Biopharma, Inc. | -48.36 Million USD | -54.511% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 19.668% |
| Sesen Bio, Inc. | -50.84 Million USD | -46.977% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 8.799% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | -505.043% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 82.518% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 28.969% |
| Athira Pharma, Inc. | -116.7 Million USD | 35.972% |
| Vaccinex, Inc. | -19.74 Million USD | -278.383% |
| HCW Biologics Inc. | -23.57 Million USD | -216.944% |
| XOMA Corporation | -39.36 Million USD | -89.835% |
| Nektar Therapeutics | -243.1 Million USD | 69.263% |
| Arvinas, Inc. | -394.8 Million USD | 81.073% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 39697.575% |
| Merus N.V. | -149.2 Million USD | 49.92% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 20.074% |
| Quince Therapeutics, Inc. | -31.26 Million USD | -139.037% |
| Rezolute, Inc. | -68.42 Million USD | -9.207% |
| Clene Inc. | -43.24 Million USD | -72.806% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -384.516% |
| BeyondSpring Inc. | -21.54 Million USD | -246.903% |
| Synlogic, Inc. | -55.16 Million USD | -35.463% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | -518.414% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | -602.152% |
| Peak Bio, Inc. | -1356.23 USD | -5509511.202% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | -130.165% |
| Krystal Biotech, Inc. | 17.9 Million USD | 517.354% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 36.902% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 78.109% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | -1522.145% |
| MannKind Corporation | 15.12 Million USD | 593.906% |
| Ikena Oncology, Inc. | -74.39 Million USD | -0.438% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | -493.369% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 467.605% |
| Gossamer Bio, Inc. | -172.15 Million USD | 56.595% |
| CohBar, Inc. | -12.06 Million USD | -519.298% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | -192.928% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -148.869% |
| Legend Biotech Corporation | -477.87 Million USD | 84.363% |
| Mural Oncology plc | -192.72 Million USD | 61.227% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 34.485% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -362.817% |
| Disc Medicine, Inc. | -91.02 Million USD | 17.909% |
| Champions Oncology, Inc. | -5.05 Million USD | -1378.492% |
| REGENXBIO Inc. | -239.46 Million USD | 68.796% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -597.161% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -34.018% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | -92.743% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 33.76% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | -112.231% |
| Cellectis S.A. | -98.09 Million USD | 23.826% |
| Longeveron Inc. | -20.06 Million USD | -272.498% |
| Repare Therapeutics Inc. | -114.27 Million USD | 34.61% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 82.986% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 0.119% |
| Revolution Medicines, Inc. | -430.58 Million USD | 82.646% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | -1088.154% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | -142.694% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | -0.178% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 1624.026% |
| Anixa Biosciences, Inc. | -10.96 Million USD | -581.468% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 101.623% |
| Denali Therapeutics Inc. | -179.97 Million USD | 58.481% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -78383.951% |
| Veru Inc. | -89.97 Million USD | 16.952% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | -178.008% |
| Cingulate Inc. | -22.95 Million USD | -225.562% |
| Passage Bio, Inc. | -98.34 Million USD | 24.016% |
| Context Therapeutics Inc. | -25.06 Million USD | -198.17% |
| Exicure, Inc. | -15.53 Million USD | -380.874% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 63.738% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | -102.085% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | -1153.196% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 55.645% |
| Nuvalent, Inc. | -149.49 Million USD | 50.015% |
| ABVC BioPharma, Inc. | -8.13 Million USD | -818.829% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 13.006% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | -147.608% |
| OmniAb, Inc. | -49.73 Million USD | -50.254% |
| Anew Medical, Inc. | -1.3 Million USD | -5644.211% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | -504.359% |
| Lipocine Inc. | -16.32 Million USD | -357.787% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | -12.079% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | -0.565% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -95.953% |
| G1 Therapeutics, Inc. | -39.01 Million USD | -91.529% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | -236.848% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 86.291% |
| Ocugen, Inc. | -64.82 Million USD | -15.265% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 19.279% |
| Q32 Bio Inc. | -86.5 Million USD | 13.617% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | -341.443% |
| Alumis Inc. Common Stock | -156.89 Million USD | 52.372% |
| Equillium, Inc. | -12.13 Million USD | -515.612% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | -27.793% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -845.46% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -296.178% |
| Galera Therapeutics, Inc. | -46.69 Million USD | -60.034% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 29.735% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -317.76% |
| Dominari Holdings Inc. | -22.44 Million USD | -232.99% |
| Edesa Biotech, Inc. | -8.19 Million USD | -812.353% |
| vTv Therapeutics Inc. | -25.41 Million USD | -194.046% |
| Bio-Techne Corporation | 326.66 Million USD | 122.875% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 80.585% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 134.532% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 43.007% |
| Candel Therapeutics, Inc. | -37.43 Million USD | -99.629% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 50.548% |
| Nkarta, Inc. | -120.48 Million USD | 37.979% |
| BioCardia, Inc. | -11.56 Million USD | -546.393% |
| Iterum Therapeutics plc | -34.58 Million USD | -116.087% |